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Regression of devil facial tumour 
disease following immunotherapy 
in immunised Tasmanian devils
Cesar Tovar1,*,, Ruth J. Pye1,*, Alexandre Kreiss1,*, Yuanyuan Cheng2, Gabriella K. Brown1,3, 
Jocelyn Darby1, Roslyn C. Malley4,5, Hannah V. T. Siddle6, Karsten Skjødt7, Jim Kaufman8, 
Anabel Silva9, Adriana Baz Morelli9, Anthony T. Papenfuss10, Lynn M. Corcoran10,11, 
James M. Murphy10,11, Martin J. Pearse9, Katherine Belov2, A. Bruce Lyons4 & 
Gregory M. Woods1,4
Devil facial tumour disease (DFTD) is a transmissible cancer devastating the Tasmanian devil 
(Sarcophilus harrisii) population. The cancer cell is the ‘infectious’ agent transmitted as an allograft by 
biting. Animals usually die within a few months with no evidence of antibody or immune cell responses 
against the DFTD allograft. This lack of anti-tumour immunity is attributed to an absence of cell 
surface major histocompatibility complex (MHC)-I molecule expression. While the endangerment of 
the devil population precludes experimentation on large experimental groups, those examined in our 
study indicated that immunisation and immunotherapy with DFTD cells expressing surface MHC-I 
corresponded with effective anti-tumour responses. Tumour engraftment did not occur in one of the 
five immunised Tasmanian devils, and regression followed therapy of experimentally induced DFTD 
tumours in three Tasmanian devils. Regression correlated with immune cell infiltration and antibody 
responses against DFTD cells. These data support the concept that immunisation of devils with DFTD 
cancer cells can successfully induce humoral responses against DFTD and trigger immune-mediated 
regression of established tumours. Our findings support the feasibility of a protective DFTD vaccine and 
ultimately the preservation of the species.
Devil facial tumour disease (DFTD) is a transmissible Schwann cell cancer1 that has decimated the Tasmanian 
devil (Sarcophilus harrisii) population2. The tumour is identified by its morphology and expression of the 
myelin-associated protein, periaxin3. Since its recognition in the far northeast of Tasmania in 1996, the disease 
has spread over most of the devils’ natural range. It has been estimated that more than 80% of the devil population 
has been killed by DFTD2. Conservation efforts are in place to protect this species, including the establishment of 
an insurance population. The objective is to reintroduce a robust and genetically diverse population into the wild. 
This can only be achieved if these devils are protected from DFTD, hence the urgent need for a vaccine.
In DFTD, the cancer cell is the ‘infectious’ agent that is transmitted as an allograft by biting2. Tasmanian dev-
ils efficiently reject allogeneic skin grafts4 and are capable of producing both cytotoxic and antibody responses 
against xenogeneic cancer cells5. We have also shown that activation of devil mononuclear cells with mitogens 
and cytokines can induce cytotoxic responses against DFTD cells in vitro6. Recently, immune responses against 
DFTD cells were also detected in a small number of animals in the wild7. However, most devils with DFTD do 
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Figure 1. Antibody responses to immunisation in protocols A to D and adjuvant control. Immunisation 
with MHC-I+ DFTD cells consistently induced antibodies responses. The left column shows a brief description 
of the immunisation protocols and the histograms in the right column show the corresponding antibody 
responses against both MHC-I+ and MHC-I− DFTD cells assessed by flow cytometry. Each colour in the 
histogram relates to a particular protocol as indicated. (a) Protocol A (TD1-My), immunisation with DFTD 
cell protein extracts did not induce antibody responses. (b) Protocol B, immunisation with MHC-I+ DFTD 
cells elicited antibodies responses particularly against MHC-I+ cells in both TD2-Ga and TD3-Ty devils. 
Immunisation with a combination of firstly sonicated and then irradiated MHC-I+ DFTD cells in Protocol C 
(c) or firstly irradiated and then sonicated in Protocol D (d) consistently induced antibody responses in the 
four devils. (e) Immunisation of the adjuvant control devil TD9-Pl followed the same regime as Protocol D but 
received only the adjuvant component of the vaccine. This devil did not produce detectable antibodies against 
DFTD cells.
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Figure 2. Histology and immunohistochemistry of DFTD tumours following challenge, showing lack of 
immune cell infiltration. (a) Sections of a biopsy of the induced tumour in TD1-My (Immunisation Protocol 
A) taken 10 weeks after challenge. There is no evidence of immune cell infiltration. (b) Development of grafted 
DFTD tumours in devils immunised with Protocol B. The biopsy sections of the tumour in TD2-Ga taken 
12 weeks after challenge show scattered MHC-II+ cells but virtually no infiltrating CD3+ cells. Similarly, 
no immune cell infiltration was detected in a biopsy of the DFTD tumour in TD3-Ty taken 10 weeks after 
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not appear to produce an immune response against the allogeneic cancer cells6,8,9. The recognition of allografts 
and malignant cells by the adaptive immune system depends on the interaction of host T cells with molecules 
of the major histocompatibility complex class I (MHC-I) expressed on the surface of nucleated cells. As DFTD 
cancer cells do not express MHC-I, this is likely to be a key mechanism by which tumour cells escape immune 
detection in devils10. Exposure of DFTD cells with IFN-γ can restore MHC-I expression10, potentially leading to 
allo-recognition and forming the basis of a vaccine.
In this study we sought to establish whether induction of MHC-I expression on DFTD cells as components 
of immunisations and immunotherapy would correspond with anti-DFTD tumour responses. To further boost 
immune recognition, the immunisations with IFN-γ treated DFTD cells were incorporated with combinations 
of ISCOMATRIX™ , Poly I:C and CpG. These adjuvants promote innate, humoral and cell mediated anti-tumour 
immunity11–13. This paper illustrates the potential for vaccination to induce humoral responses and, with addi-
tional immunotherapy, trigger DFTD immune-mediated regression in vivo.
Results
The aim of the current study was to explore immunisation protocols to enhance protective responses against 
DFTD. These included immunisation with DFTD cells expressing MHC-I to increase their antigenicity, in com-
bination with ISCOMATRIX™ , Poly I:C and CpG, adjuvants that enhance both innate and adaptive immune 
responses. As access to Tasmanian devils for research purposes is limited, we were restricted to the use of nine 
healthy devils, some of which had reached an advanced age. These devils were used over a five-year period. In an 
endeavour to improve the immune response, four immunisation protocols were tested sequentially. Seven devils 
were immunised with a variety of cell preparations and adjuvants to determine if they could be protected against 
the development of DFTD following challenge with live DFTD cells. One devil was used as an adjuvant-alone 
control and one devil as a non-immunised control. Devils were monitored for adverse reactions to the immu-
nisations and none were identified. In the absence of a reliable cytotoxicity assay we used DFTD-specific IgG 
antibody levels in devil serum to evaluate the immune responses after the immunisations in each protocol. As 
devils were immunised with either MHC-I+ or MHC-I− DFTD cells, antibody reactivity was evaluated against 
cytokine treated (MHC-I+) and untreated (MHC-I−) DFTD cells. As IgG production requires T cell help, this 
also provided an indicator of T cell involvement. Six of the immunised devils and the non-immunised control 
devil were later challenged with live DFTD cells. If tumours developed, immunotherapy was commenced and 
tumour rejection and anti-tumour antibody responses were measured. Tumour biopsies were taken before and 
after immunotherapy, and evaluated for immune cell infiltration by immunohistochemistry. An outline of the 
immunisations, challenges and tumour development is presented in Supplementary Table S1.
A comparison of the four protocols can be seen in Figs 1–4. The responses to immunisation are shown in Fig. 1 
and highlight that immunisation with MHC-I+ DFTD cells consistently produced antibody responses. Figure 2 
shows the histology of the engrafted DFTD tumours, which occurred in six of the seven devils challenged with 
live tumour cells. Immunohistochemistry did not reveal evidence of immune cell infiltration into the tumours. 
Figure 3 outlines the growth of the engrafted tumours and their response to immunotherapy. Immunotherapy 
with live MHC-I+ DFTD cells was associated with tumour regression in three devils and the regression correlated 
with antibody responses against DFTD cells. The histology in Fig. 4 supports the immune-mediated regression of 
the tumours as indicated by the large numbers of MHC-II and CD3 positive cells infiltrating the tumour.
The following sections describe the assessment of the responses to immunisation and immunotherapy in each 
protocol.
Protocol A. Devil TD1-My was immunised subcutaneously three times with protein extracted from 
heat-treated DFTD cells and boosted six months after the third immunisation. Each immunisation and the 
booster used the ISCOMATRIX™ adjuvant. This devil did not show any evidence for an antibody response 
against the DFTD cells (Fig. 1a). While there was no DFTD-specific antibody response detectable in the in vitro 
assay, an in vivo immune response may have occurred. To test this, the devil was challenged with 25,000 live 
DFTD cells one month after the booster immunisation in one site in the rump. A tumour was detected 37 days 
after this challenge. DFTD was confirmed on biopsy by periaxin expression and there were no signs of immune 
cell infiltration in the tumour (Fig. 2a).
The lack of an antibody response indicated that the DFTD cells were poorly recognised by this devil’s immune 
system. When the tumour in this animal reached approximately 30 cm3 and with no signs of regression, the devil 
was injected subcutaneously with live interferon-γ (IFN-γ ) treated MHC-I+ DFTD cells between the shoulder 
blades. As DFTD cells cultured with IFN-γ upregulate MHC-I expression9, they have the potential to become 
the challenge. (c) TD4-Mm (Protocol C) did not develop tumours after the challenge with live DFTD cells. 
(d) Development of grafted DFTD tumours in devils immunised with Protocol D. TD6-Tp developed 
DFTD tumours after challenge at both sides of injection (left hand side - LHS, and right hand side - RHS of 
the rump). The images are representative histology of a biopsy from the LHS tumour taken 14 weeks after 
challenge showing very poor immune cell infiltration. TD7-Sy also developed DFTD tumours at both sides 
of injection. The images show no evidence of immune cell infiltration in a biopsy of the LHS tumour taken 20 
weeks after challenge. (e) The adjuvant control (TD8-Mk) developed tumours at both sides of the challenge. 
A biopsy of the LHS tumour taken 10 weeks after challenge shows scattered MHC-II+ cells within the tumour 
and very occasional CD3+ cells. All panels (a to e) standard haematoxylin and eosin (H&E) staining and 
immunohistochemical labelling using anti-periaxin (PRX) antibody to detect DFTD tumour cells and anti-
MHC-II and anti-CD3 antibodies to detect an immune response. Scale bar, 50 μ m
www.nature.com/scientificreports/
5Scientific RepoRts | 7:43827 | DOI: 10.1038/srep43827
Figure 3. Tumour growth and antibody responses following immunotherapy. Tumour regression associated 
with antibody responses was observed in three devils after therapy with live MHC-I+. Graphs on the left show 
a time-line of the growth of the induced tumours following challenge with live DFTD cells (day 0) for each 
protocol (a to d) and the no-immunisation control (e). Immunotherapy protocols are indicated in coloured 
vertical dashed lines. Histograms on the right show the antibody responses after the therapy assessed by flow 
cytometry against both MHC-I− and MHC-I+ DFTD cells. (a) Protocol A, immunotherapy in TD1-My induced 
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targets for an allogeneic immune response. The original tumour continued to increase in size, but after one week it 
began to regress (Fig. 3a). To maintain the response, a cytokine rich conditioned medium (supernatant obtained 
from mitogen stimulated devil lymphocytes) was injected intra-tumourally each week for three weeks. This was 
followed by an additional injection of live MHC-I+ DFTD cells near the tumour. The tumour continued to regress 
until it was no longer palpable four weeks after the last immunotherapy (Fig. 3a).
One week after all treatments were completed, the serum contained elevated levels of antibodies against 
MHC-I+ DFTD cells, almost 30 times the median fluorescence intensity (MFI) of the pre-immune serum. 
Antibodies against MHC-I− DFTD cells were also detected, but at lower levels (Fig. 3a). A tumour biopsy, taken 
a week after regression was first detected, showed sparse DFTD cells, with a strong infiltration of MHC-II+ cells 
and CD3+ cells (predominantly CD8+) into the tumour (Fig. 4a, Supplementary Table S2). Table 1 describes the 
immunotherapy and summarises the immune response to the therapy.
Due to an age-related health problem, this devil was euthanised 40 weeks after the last treatment. There were 
no signs of tumour recurrence or metastases during post-mortem examination. The remarkable T cell infiltration 
into the tumour and the strong antibody response provided the first evidence that immunotherapy can stimulate 
the devil’s immune system to recognise and target an established DFTD tumour. One concern was that immuno-
therapy with live MHC-I+ DFTD cells could pose a risk of tumour engraftment at the tumour immunotherapy 
site. Therefore, when immunisation protocols failed to protect against experimentally induced DFTD the subse-
quent immunotherapy was inoculation with irradiated IFN-γ treated MHC-I+ DFTD cells (to mimic intact live 
MHC-I+ DFTD cells) and IFN-γ therapy (protocol B).
Protocol B. Two devils, TD2-GA and TD3-Ty were immunised with frozen/thawed DFTD cells that had 
been treated with either Trichostatin A (TSA), a histone deacetylase inhibitor (TD2-Ga) or cytokine rich con-
ditioned medium (TD3-Ty) to upregulate MHC-I expression. The adjuvant ISCOMATRIX™ was used in all 
immunisations.
TD2-Ga developed low to medium antibody responses against IFN-γ treated MHC-I+ DFTD cells and 
untreated DFTD cells (Fig. 1b). The devil was then challenged with 25,000 live DFTD cells and a DFTD tumour 
was first identified at the inoculation site 67 days after challenge. Immunohistochemistry at this time showed few 
MHC-II+ cells and occasional CD3+ cells, mostly located at the periphery of the tumours or in proximity to blood 
vessels. (Fig. 2b). Cells with dendritic morphology, presumably dendritic cells, were seen in the epidermis, dermis 
and subcutaneous tissue, but not associated with the tumours (Supplementary Table S2).
When the tumour reached approximately 20 cm3 in volume the devil was subcutaneously injected, on the 
rump near the tumour, with irradiated MHC-I+ DFTD cells followed one week later by an intra-tumoural 
injection of devil recombinant IFN-γ , which became available for the first time. The tumour continued to grow 
(Fig. 3b). For the duration of the immunotherapy, devil TD2-Ga maintained medium levels of antibodies against 
IFN-γ treated MHC-I+ and untreated DFTD cells (Fig. 3b). Tumour biopsies showed very few MHC-II+ cells 
and occasional T cells were present, but mostly in the surrounding connective tissue (Fig. 4b). This devil died 
naturally of an unrelated cause. A post-mortem showed an encapsulated DFTD tumour with strong evidence of 
tumour vascularisation including large blood vessels within the tumour. Few MHC-II+ and T cells were identified 
within the tumour. MHC-II+ and T cells were present in the granulation tissue and connective tissue away from 
the tumour. (Supplementary Table S2). Table 1 provides a summary of the immune responses to therapy.
TD3-Ty developed a low antibody response post-immunisation, but only against IFN-γ treated MHC-I+ 
DFTD cells (Fig. 1b). A DFTD tumour was first identified at the inoculation site 67 days after challenge with 
25,000 live DFTD cells. Immunohistochemistry revealed almost no immune cell infiltration within the tumour 
(Fig. 2b). MHC-II+ and CD3+ cells were scarce, and when present were located at the periphery of the tumours 
or in proximity to blood vessels (Supplementary Table S2).
When the tumour reached approximately 20 cm3 in volume the devil received an intra-tumoural injection of 
IFN-γ each week for three weeks. The tumour continued to grow rapidly. Two weeks after the last dose of IFN-γ 
this devil was injected subcutaneously, on the rump near the tumour, with irradiated IFN-γ treated MHC-I+ 
DFTD cells (Fig. 3b). At this time the tumour appeared to ulcerate and it dislodged from the skin. A biopsy of 
the tumour site revealed granulation tissue, fibroblasts with an activated-like appearance and a small amount 
of necrotic tumour. Large dendritic MHC-II+ cells were identified in the periphery of the necrotic tumour cells 
complete tumour regression and was associated with high levels of antibody, particularly against MHC-I+ 
DFTD cells. (b) Protocol B, immunotherapy in TD2-Ga was ineffective and the tumour grew. Antibodies 
were detected against both MHC-I− and MHC-I+ DFTD cells. Immunotherapy in TD3-Ty was ineffective in 
controlling tumour growth. The tumour ulcerated and dislodged from the skin. A few weeks later the tumour 
re-established and continued to increase in size. Antibodies were not detected in the serum. (c) Protocol C. 
TD4-Mm did not develop tumours after challenge. This devil died 189 days after challenge. A post-mortem 
examination did not detect DFTD tumours or metastases. (d) Protocol D. Immunotherapy in TD6-Tp 
consisting of a single injection of live MHC-I+ DFTD cells given in the interscapular region induced complete 
regression of both tumours. The same immunotherapy in TD7-Sy also induced complete regression of both 
tumours. A small third tumour developed in the site of the immunotherapy injection. This tumour did not 
increase in volume and immune cell infiltration was observed in histology (see Supplementary Table S2). Both 
devils TD6-Tp and TD7-Sy had elevated serum antibodies against DFTD cells. (e) The therapy administered to 
the no-immunisation control (TD8-Mk) was ineffective and both tumours grew. A third tumour developed in 
the site of the immunotherapy and this tumour also continued to increase in size. Antibodies were not detected 
after therapy.
www.nature.com/scientificreports/
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associated with CD3+/CD8+ cells. Biopsies taken one, three and four weeks later showed the re-establishment 
of nests of DFTD tumours suggesting that dislodgment of the tumour may have been mechanical, and not due 
to an immune process (Supplementary Table S2). Serum antibodies against DFTD cells were not detected after 
treatment (Fig. 3b). MHC-II+ and CD3+ cells were present around the periphery of the tumour clusters but very 
few infiltrated the tumour (Fig. 4b). The tumour continued to grow and this devil was euthanised. A summary of 
the immunotherapy and the immune response to the therapy is described in Table 1.
From the immunisation of TD2-Ga and TD3-Ty, it was concluded that MHC-I+ DFTD cells induced better 
DFTD-specific IgG antibody responses. However, the immunisation protocol alone was not enough to induce an 
effective anti-tumour immune responses. Therefore, additional adjuvants were used in subsequent immunisation 
protocols.
Protocol C. Two devils (TD4-Mm and TD5-Br) were immunised with sonicated DFTD cells that had been 
treated with IFN-γ to upregulate MHC-I (immunisation 1), followed by irradiated, IFN-γ treated DFTD cells 
(immunisation 2) and boosters with irradiated MHC-I+ DFTD cells. In all immunisations/boosters the adjuvants 
ISCOMATRIX™ , Poly I:C and CpG were used.
TD4-Mm produced medium antibody responses against IFN-γ treated MHC-I+ and untreated DFTD cells 
(Fig. 1c). Two booster injections of irradiated MHC-I+ DFTD cells six and eleven months after the last immu-
nisation did not appear to increase the antibody levels (Fig. 1c). This devil remained free of DFTD tumours for 
189 days after challenge with live DFTD cells but was euthanized for age-related health reasons. Medium to high 
Imm. 
Protocol Challenge and immunotherapy protocol
Tumour 
engraftment 
(palpable 
tumours)
Antibody response 
against DFDT cellsa Immune cell infiltrationb
Tumour 
regression
MHC-I 
(−)
MHC-I 
(+) CD3+ CD8+ CD4+
MHC-
II+
A
TD1-My
Challenge with live DFTD cells 37 days
Therapy: one dose of live conditioned medium-treated 
DFTD cells + + + + + + + + + + + + + + + 
YesTherapy: 3 doses of conditioned medium intratumoural NA NA + + + + + + + + + 
Therapy: one dose of live conditioned medium-treated 
DFTD cells + + + + + + + + + + − + + + 
B
TD2-Ga
Challenge with live DFTD cells 67 days + + + + 
Therapy: one dose of irradiated IFN gamma-treated 
DFTD cells + + + + + + + + 
NoTherapy: one dose of IFN gamma intratumoural NA NA + + + -
TD3-Ty
Challenge with live DFTD cells 67 days − − 
Therapy: 3 doses of IFN gamma intratumoural − − + + + + 
NoTherapy: one dose of irradiated IFN gamma-treated 
DFTD cells + + + + + + + + 
C
TD4-Mm Challenge with live DFTD cells
No evidence 
of tumour 
development
+ + + + + 
TD5-Br Euthanised before challenge
D
TD6-Tp
Challenge with live DFTD cells at the left and right 
hand side of the rump 80 days Yes
Therapy: live IFN gamma-treated DFTD cells + + + + + + + + + + + + 
TD7-Sy
Challenge with live DFTD cells at the left and right 
hand side of the rump 110 days + + + + Yes
Therapy: live IFN gamma-treated DFTD cells + + + + + + + + + + + + + + + + + 
Control
TD-9 Mk
Challenge with live DFTD cells at the left and right 
hand side of the rump 40 days No
Therapy: live IFN gamma-treated DFTD cells − − + /- + /− + /− + 
Table 1.  Summary of antibody and cellular responses to immunotherapy. aFlow cytometry analysis. The 
median fluorescence intensity ratio (MFIR) was used to classify the antibody responses. The MFIR is the 
median fluorescence intensity (MFI) of DFTD cells labelled with immune serum divided by the MFI of DFTD 
cells labelled with pre-immune serum. The responses were considered. − MFIR < 1.5 times the pre-immune 
response. + MFIR 1.5 to 2 times the pre-immune response. + + MFIR 2 to 4 times the pre-immune response.  
+ + + MFIR > 4 times the pre-immune response. b Immune cell infiltration assessed by immunohistochemistry. 
- No cells in the tumour or surrounding stroma. + /− Few cells in the stroma but not infiltrating the tumour.  
+ Occasional cells in the tumour. + + Few scattered cells in the tumour. + + + Large number of cells within the 
tumour. NA Not assessed.
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antibody responses against IFN-γ treated MHC-I+ DFTD cells and untreated DFTD cells were detected after the 
live tumour cell challenge and similar levels identified in the post-mortem sample (Table 1).
TD5-Br produced medium antibody responses against IFN-γ treated MHC-I+ and untreated DFTD cells 
(Fig. 1c). This devil was euthanized for age-related health reasons before it was challenged with live DFTD cells.
Figure 4. Tumour histology and immunohistochemistry of DFTD tumours following immunotherapy 
showing tumour regression and immune cell infiltration. (a) Protocol A. Biopsy sections of the tumour site 
of TD1-My taken one week after completion of immunotherapy. Tumour regression correlated with strong 
immune cell infiltration of MHC-II+ cells and T cells, mainly CD8+ cells. (b) Protocol B. A tumour biopsy 
taken one week after the last therapy in TD2-Ga shows no evidence of immune cell infiltration. Biopsies of the 
scar tissue 3 weeks after dislodgment of the tumour in TD3-Ty show the persistence of few DFTD (PRX+ ) cells 
and a large number of MHC-II+ cells but very few CD3+ cells. (c) Protocol D. Tumour regression in TD6-Tp 
and TD7-Sy correlated with strong immune cell infiltration of MHC-II+ cells and CD3+ cells with CD8+ cells 
more abundant than CD4+ cells as evidenced by biopsies taken 4 weeks after therapy. (d) No-immunisation 
control (TD8-Mk), a biopsy of the LHS tumour taken 4 weeks after therapy shows well established DFTD 
tumours with virtually no immune cell infiltration. Standard haematoxylin and eosin (H&E) staining and 
immunohistochemical labelling using anti-periaxin (PRX) antibody and anti-MHC-II, CD3, CD8 and CD4 
antibodies. Scale bar, 50 μm.
www.nature.com/scientificreports/
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Immunisation Protocol C showed the first preliminary evidence that the combination of adjuvants led to a 
stronger anti-tumour antibody response. It is feasible that this strong immune response also prevented experi-
mental DFTD tumour engraftment.
Protocol D. Two devils (TD6-Tp and TD7-Sy) were immunised with irradiated DFTD cells that had been 
treated with IFN-γ to upregulate MHC-I (immunisation 1), followed by sonicated, IFN-γ treated MHC-I+ DFTD 
cells (immunisation 2) and a booster with irradiated MHC-I+ DFTD cells. All immunisations/boosters were in 
combination with ISCOMATRIX™ , Poly I:C and CpG adjuvants.
TD6-Tp produced medium antibody responses against IFN-γ treated MHC-I+ DFTD cells and untreated 
DFTD cells, but only after receiving the second immunisation (Fig. 1d). 80 days following challenge with 25,000 
live DFTD cells at the right hand side (RHS) of the rump and 100,000 live DFTD cells at the left hand side (LHS) 
of the rump, DFTD tumours developed at both sites. The higher dose was used to confirm that if a tumour did 
not develop, it was not due to insufficient cells being inoculated. Immunohistochemistry of the LHS tumour 
revealed only a few MHC-II+ and CD3+ cells mainly at the periphery of the tumour cell nests (Fig. 2d). When 
this tumour reached approximately 20 cm3 in volume the devil was subcutaneously injected in the interscapular 
region (between the shoulders blades), with live IFN-γ treated MHC-I+ DFTD cells. One week later the origi-
nal tumours began to regress (Fig. 3d). Low to medium antibody responses against IFN-γ treated MHC-I+ and 
untreated DFTD cells were evident after immunotherapy (Fig. 3d). Biopsies of the LHS tumour, four weeks after 
immunotherapy, revealed moderate numbers of MHC-II+ cells towards the tumour periphery and a few within 
the tumour. A large number of CD3+ cells showed a similar distribution to the MHC-II+ cells, with CD8+ cells 
more abundant than CD4+ cells (Fig. 4c). Neither tumour (LHS and RHS) was palpable 70 days after immuno-
therapy commenced. Biopsies at the LHS tumour site showed scar tissue composed of hyalinised and relatively 
acellular dense connective tissue. Evidence of immune infiltration was indicated by moderate to large numbers of 
MHC-II+ cells, individually or in clusters, adjacent to the connective tissue. Similarly, a moderate to high number 
of CD3+ T cells paralleled the MHC-II+ cells (Supplementary Table S2).
TD7-Sy produced medium/high antibody responses against IFN-γ treated MHC-I+ DFTD cells and untreated 
DFTD cells after receiving immunisation 1. Responses increased after immunisation 2 (Fig. 1c). This devil was 
challenged with live DFTD cells at the RHS and LHS of the rump as described above and DFTD tumours devel-
oped at both inoculation sites 110 days later. Immunohistochemistry of the LHS tumour revealed limited immune 
cell infiltration (Fig. 2d). When the LHS tumour reached approximately 30 cm3 in volume the devil was subcuta-
neously injected, in the interscapular region, with live IFN-γ treated MHC-I+ DFTD cells. The tumours increased 
in size, but one week later both tumours began to regress (Fig. 3d). Medium to high antibody responses against 
IFN-γ treated MHC-I+ DFTD cells and untreated DFTD cells were evident after treatment (Fig. 3d). Biopsies 
of the LHS and RHS tumours, four weeks after immunotherapy, revealed moderate numbers of MHC-II+ cells 
towards the periphery of the tumour and some cells within the tumour. A large number of CD3+ cells showed a 
similar distribution to the MHC-II+ cells, with CD8+ cells more abundant than CD4+ cells (Fig. 4c). The LHS and 
RHS tumours were not palpable 70 days after treatment commenced.
With devil TD7-Sy, the live MHC+ DFTD cells that were used for immunotherapy developed into a small 
tumour (Fig. 3d). This tumour did not increase in volume after it had reached 10 cm3. MHC-II+ and CD3+ cells 
could be found throughout the tumour (Supplementary Table S2). A summary of the immunotherapy and the 
immune response to the therapy is described in Table 1.
Immunisation protocol D produced antibody responses to DFTD cells. Although this did not protect from 
tumour development, immunotherapy with a single injection of live MHC-I+ DFTD cells was followed by 
immune cell infiltration and tumour regression.
Non-immunised control devil. TD8-Mk was not immunised and did not receive adjuvant. 40 days after 
challenge with live DFTD cells, tumours were palpable at both the 25,000 and 100,000 cell inoculation sites. 
The tumours continued to grow, with no indication of immune cell infiltration (Fig. 2e). When the tumour 
reached approximately 10 cm3 in volume the devil was subcutaneously injected, in the interscapular region, 
with live IFN-γ treated MHC-I+ DFTD cells. For this devil, the immunotherapy via injection of live MHC-I+ 
DFTD tumour cells produced a small tumour (Fig. 3e). There was no evidence for antibody production (Fig. 3e). 
Biopsies taken 28 days after the immunotherapy showed well established and encapsulated tumours. Average to 
large sized intra-tumoural blood vessels and extensive necrosis between the pockets of tumours were observed 
(Supplementary Table S2). A few foci of MHC-II+ cells appeared in the periphery of the tumours with very few 
within the tumour. Very few CD3+ (either CD4 and CD8) T cells were found within or surrounding the tumour 
(Fig. 4d). Due to the progression of tumour size, this devil was euthanised. Table 1 describes the immunotherapy 
and summarises the immune responses.
Adjuvant control devil. TD9-Pl received five injections of the adjuvant components only (i.e. excluding 
DFTD cells) and did not produce detectable anti-DFTD antibodies (Fig. 1e). This devil was not challenged with 
live DFTD cells.
MHC-I genotypes within the test cohort. Devils have three classical MHC-I genes, Saha-UA, -UB and 
-UC, with Saha-UA converted to a pseudogene in certain MHC haplotypes due to a 1.6-kb-long deletion in the 
genomic region14. All nine devils (seven immunised and two controls) and the DFTD tumour cell line were gen-
otyped at these three loci for the peptide-binding domains (α 1 and α 2; Supplementary Table S3).
A total of 18 MHC-I variants was identified across all samples; 12 have been previously reported and assigned 
to MHC loci based on BAC contig assembly and sequencing and genotype analysis14,15, whereas six are novel 
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variants (SahaI*35:02, 88:02, 99, 100, 101, and 102; GenBank accession numbers KY194692- KY194697). These 
were assigned to gene UA, UB or UC based on their phylogenetic relationship with previously reported variants 
(Supplementary Fig. S1). Four MHC-I variants, SahaI*35, 46, 90 and 28, were identified in the DFTD cells used 
in the immunisation and immunotherapy procedures. This result differs from the previously reported MHC 
genotype of the tumour (Pye et al. 2015), which is likely due to the use of different starting material. The previous 
study used tumour biopsies (Pye et al. 2015), which usually contain host connective tissue (Siddle et al.10 PNAS), 
whereas in this study tumour DNA was extracted from cell culture and therefore was unlikely to contain host 
DNA contamination. The other 14 MHC-I variants showed high sequence similarities (94.2% average amino acid 
sequence identity; Supplementary Table S4) with the four variants in the tumour, consistent with previous find-
ings of low sequence variability in devil MHC genes14. Two control devils each shared one MHC-I antigen with 
DFTD cells (SahaI*35 in TD9-Pl and SahaI*28 in TD8-Mk), while five of the seven immunised devils, TD1-My 
(Protocol A), TD2-Ga and TD3-Ty (Protocol B), TD6-Tp and TD7-Sy (Protocol D), did not share any MHC-I 
molecules with the tumour. TD1-My (protocol A) had one MHC-I variant (SahaI*101) with relatively lower 
sequence similarity (89.2%) with one of the tumour antigen (SahaI*90). This animal produced lower antibody 
responses against MHC-I+ DFTD cells post-immunisation and post-booster than the other devils (Fig. 1). Of the 
two devils in protocol B, TD2-Ga appeared to produce stronger antibody responses than TD3-Ty. This may be 
attributed to TD2-Ga possessing MHC-I variant SahaI*87, which shows the lowest sequence identity among all 
variants to SahaI*46 (89.2%) and SahaI*28 (89.7%) of the tumour. The two devils in protocol C produced good 
immune responses even though they shared one and two MHC-I molecules with tumour cells. The two devils in 
protocol D, TD6-Tp and TD7-Sy, had similar MHC-I genotypes, both possessing variants SahaI*29, 36, 37 and 
27. Both produced responses against DFTD cells.
Discussion
Transmissible cancers rarely occur in nature and have only been recorded in domestic dogs, Tasmanian devils 
and shellfish16–20. Devil facial tumour disease has caused a devastating reduction in the wild devil population21. 
Intervention is required to prevent extinction of the wild population. Currently, healthy Tasmanian devils are kept 
in breeding programs as an insurance population with the goal of reintroducing healthy and genetically diverse 
devils into the wild. But releasing them into the wild will expose them to DFTD, hence the need for vaccination 
to protect them. For a vaccine to be effective it needs to induce an immune response against the cancer cells and 
show evidence of efficacy in vivo. Here we show the potential of immunisation strategies using DFTD cancer cells 
to induce immune responses against DFTD cells and regression of established tumours in devils.
Research on the Tasmanian devil is constrained due to the endangered status of the species. Despite this it 
was possible to test four immunisation protocols and to cautiously provide conclusions. For example, immuni-
sation protocols C and D produced specific antibodies against MHC-I+ and MHC-I− DFTD cells, thus immu-
nisation with sonicated and irradiated MHC-I+ cells in the presence of multiple adjuvants promotes anti-DFTD 
responses. This immune response may have protected from DFTD development following challenge with live 
tumour cells. One immunised devil (TD4-Mm) did not develop DFTD and two immunised devils appeared to 
have a delayed onset of DFTD (TD6-Tp and TD7-Sy) compared to the single non-immunised control. Validation 
of these conclusions requires additional devils. This is particularly relevant for the non-immunised controls to 
more accurately determine time to tumour development and evidence for spontaneous regression, as occurs with 
experimental inoculation of dogs with canine transmissible venereal tumour (CTVT), the other transmissible 
tumour in a mammalian species20. Ethically it was undesirable to challenge additional devils knowing they would 
develop DFTD.
Devil
Antibody response to 
immunisation
Immunotherapy
Antibody 
response following 
immunotherapy
Immune cell 
infiltrationMHC-I- MHC-I+
Tumour regression
TD1-My
Negative Not assessed
Live MHC-I+ DFTD 
cells Increased
Dense(Protocol A)
TD6-Tp
Medium Medium
(Protocol D)
Dense
TD7-Sy
Medium Medium
(Protocol D) Dense
No tumour regression
TD2-Ga
Low Medium
Irradiated MHC-I+ 
DFTD cells
Did not change
(Protocol B)
Sparse
TD3-Ty
Negative Medium
(Protocol B)
Sparse
TD8-Mk Live MHC-I+ DFTD 
cells(Non-immunised control) Sparse
Table 2.  Comparison of immune responses in devils with regressed and non-regressed DFTD tumours.
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The development of DFTD tumours in devils immunised with DFTD cells and challenged with live DFTD 
cells, provided an opportunity to treat these devils with immunotherapy and evaluate an anti-tumour immune 
response in vivo. Our approach took advantage of the potential strong allogeneic responses induced by MHC 
incompatibilities. We injected devils with live DFTD cells that had been cultured in vitro with IFN-γ to upregulate 
MHC-I and three of the six devils with DFTD tumours underwent regression.
We recently provided evidence for tumour regression in a small proportion of wild devils with DFTD7. The 
presence of antibodies to DFTD cells in the wild devils that recovered provided evidence that regression was 
immune mediated. The identification of immune cell infiltration into the tumours undergoing regression in the 
experimental devils provides compelling evidence that DFTD tumours can be targeted and eliminated by the 
immune system.
Evaluation of the devils that showed tumour regression revealed three salient features (Table 2):
Firstly, regression correlated with prior immunisation with DFTD cells and there was a rise in antibody 
levels to DFTD cells following the immunotherapy. The priming effect appeared to be the combined action of 
the immunisation protocol and the adjuvants. ISCOMATRIX™ is a proprietary saponin based adjuvant, which 
is known to elicit a broad antibody response. This adjuvant induces the generation of antigen-specific CD8+ 
T cells and when combined with Toll-like receptor (TLR) agonists, causes the regression of established solid 
tumours12,13,22,23. We also used the TLR agonists CPG-1585 and CPG-2395, which stimulate via TLR9, and Poly 
I:C, which stimulates via TLR3. The combination of adjuvants in our vaccine is likely to engage multiple signalling 
pathways that support adaptive cellular immune responses in the Tasmanian devil.
Secondly, remission occurred in devils injected with live IFN-γ treated DFTD cells. Immunotherapy using 
live proliferating, but not irradiated, DFTD cells expressing surface MHC-I correlated with the cellular immune 
response observed at the tumour engraftment site. Proliferating DFTD tumour cells expressing MHC-I provide 
tumour antigens for presentation and the prior immunisation may allow presentation to memory cells, enabling 
more DFTD-specific T cells to be activated. We have recently shown that activated Tasmanian devil mononuclear 
cells can kill DFTD cells in vitro6.
Thirdly, remission correlated with T cell and MHC-II+ cell (potentially dendritic cell) infiltration into the 
DFTD tumour. The presence of tumour infiltrating lymphocytes, mostly CD3+ and CD8+, indicates an immu-
nologically mediated regression. Indeed, after immunotherapy, we observed increased levels of IgG anti-DFTD 
antibodies in devils subjected to Protocols A and D. As IgG antibodies are T cell dependent it provides further 
evidence for a T cell anti-tumour immune response. This was clearly different to the three devils that did not show 
signs of remission as there was no indication of immune cell infiltration into the tumour. All devils that did not 
undergo remission had low to modest antibody levels, with no evidence for an increase after immunotherapy.
The analysis of MHC type and response to immunisation and immunotherapy is consistent with MHC incom-
patibilities inducing alloreactivity. The non-immunised control devil that did not respond to immunotherapy 
had a number of MHC ‘mismatches’ with the DFTD tumour cells. The failure of this devil to produce an immune 
response against live DFTD cells that had been treated with IFN-γ is consistent with the need for prior immuni-
sation and highlights the complexity faced with developing a vaccine and/or immunotherapy. Cells exposed to 
IFN-γ , not only upregulate MHCI/II, but have also been found to upregulate expression of immune inhibitory 
molecules, such as B7-H1/PD-L1, in human and mouse tumour cell lines24.
Taken together, our results highlight the feasibility of developing a vaccine to counter the devastating 
Tasmanian devil facial tumour disease. The immune system of the Tasmanian devil is able to mount specific 
humoral and cellular responses to facilitate the eradication of established tumours. DFTD cells cultured in IFN-γ 
upregulate MHC-I and by incorporating preparations of these cells with adjuvants that target TLRs25 immune 
responses against the tumour cells are consistently produced. One potential complication could be the upregula-
tion of PD-L1, which also occurs following IFN-γ exposure26. However, PD-L1 could also provide a useful target 
for immunotherapy, which has been successfully used for human cancers. An additional complication could be 
the discovery of a second transmissible cancer, DFT219. A key challenge is to develop a strategy to protect against 
both DFTDs. The immunisations alone in this study did not completely prevent tumour engraftment, indicat-
ing that stronger protective immune responses will be required. Further studies are required to dissect both the 
immune and tumour suppressor mechanisms at play, and to find opportunities for blocking them, before we can 
develop effective immune control of DFTD.
Methods
Tasmanian devils and biological samples. The Tasmanian devils were housed in secured shelters 
in accordance with the guidelines of the Department of Primary Industries, Parks, Water and Environment 
of Tasmania (DPIPWE). All animal procedures were approved by the University of Tasmania Animal Ethics 
Committee under A009215, A0011436 and A0013685. All devils (6 females and 3 males) were adults with ages 
ranging from 5 to 7 years at commencement of experiments (Supplementary Table S5). All experimental methods 
were performed in accordance with the University of Tasmania guidelines.
Immunisation, blood collection, live cell challenge and therapy were performed under anaesthesia induced 
with 5% Isoflurane reducing to 3% via a mask (ISOTHESIA® (Henry Schein, Northgate, Australia). 10 ml of 
blood was obtained from the jugular vein as previously described27. Up to 4 ml of blood was placed into clot acti-
vating tubes (Greiner Bio-one) for serum analysis and the remainder into lithium heparin anticoagulant tubes 
for cell analyses. Tumour biopsies were collected using sterile 4 mm disposable biopsy punches (Kai Medical). 
Biopsies were divided with a scalpel blade and half placed into 1 ml 10% neutral buffered formalin and half into 
1 ml RNAlater.
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DFTD cell line culture conditions. The DFTD cell line C5065 (strain 3) was used for all experiments 
and was provided by A-M. Pearse and K. Swift of the DPIPWE. The cell line was maintained in RPMI 1640 cul-
ture medium (Life Technologies), supplemented with 10% heat inactivated foetal bovine serum (Bovogen), 1% 
GlutaMAX™ (Life technologies) and 1% Antibiotic-Antimycotic (Life Technologies) in a 35 °C humidified 5% 
CO2 incubator. When required, the cells were gently flushed from their culture surface using culture medium 
and pelleted by centrifugation at 500 g for 5 min. Cell viability counts were performed on an improved Neubauer 
chamber.
Preparation of DFTD cells for immunisation and challenge. Four immunisation protocols (A-D) 
were evaluated. Complete details for dose, route, frequency of administration and vaccine composition for each 
immunisation protocol are indicated in Supplementary Table S6. Protocol D also included an adjuvant control 
devil that received four immunisations of the adjuvant components only (i.e. excluding DFTD cells).
MHC-I was upregulated in DFTD cells by treatment with either: (i) 10% cytokine rich conditioned medium 
(supernatant of Tasmanian devil MNC stimulated with 5 μ g/ml Concanavalin A for 48 h) incubated for 48 h; (ii) 
Trichostatin A - TSA (Sigma-Aldrich) at 10 ng/ml in culture for 72 h; (iii) IFN-γ at 1/5,000 dilution in culture for 
24 h; or (iv) 10% cytokine rich conditioned medium plus recombinant devil IFN- γ at 1/10,000 dilution in culture 
for 24 h.
The antigenic component of the vaccines included total protein extracted from DFTD cells that were 
heat-treated at 56 °C for one hour; DFTD cells inactivated by freeze/thawing cycles (10 quick cycles of freezing 
in liquid nitrogen and thawing in a 40 °C water bath); DFTD cells inactivated by radiation (two doses of 40 Gy 
of gamma radiation 24 h apart using a Varian Clinac 23-EX linear accelerator – Varian Medical Systems Inc.); or 
sonicated DFTD cells (four ultra-sonic cycles using 50% power using an ultrasonic cell disruptor – Misonix Inc.).
Adjuvants included ISCOMATRIX™ adjuvant (provided by CSL Ltd, Victoria, Australia) and the TLR ago-
nists CpG oligonucleotide 1585 (CpG 1585, GeneWorks); CpG oligonucleotide 2395 (CpG 2395, GeneWorks) or 
poly(I:C) (poly I:C, Sigma-Aldrich).
Five immunised devils (TD1-My, TD2-Ga, TD3-Ty, TD4-Mm) were challenged with a single dose of 25,000 
live DFTD cells (cell line C5065) resuspended in 0.25 ml of PBS injected subcutaneously into to the rump. Two 
immunised devils (TD6-Tp and TD7-Sy) and the non-immunised control (TD8-Mk) were challenged with 
100,000 live DFTD cells in 1 ml of PBS into the left-hand side of the rump and 25,000 live DFTD cells into the 
right-hand side of the rump. The areas of injection were shaved for easier visualization and to mark the location. 
The devils were examined monthly under anaesthesia for evidence and measurement of tumours.
Immunotherapy. A range of treatments were tested on the devils that developed tumours after the chal-
lenge. Therapies included administration of: (i) cytokine rich conditioned medium injected into the tumour; 
(ii) live cytokine-treated DFTD cells injected subcutaneously; (iii) cytokine-treated and then irradiated DFTD 
cells injected subcutaneously; and (iv) recombinant devil IFN-γ injected into the tumour. Details of the therapy 
protocols are indicated in Supplementary Table S7.
Antibody responses analysis. Washed DFTD tumour cells (100 μ l at 2 × 106/ml diluted in washing buffer 
−0.5% BSA in PBS) were placed in wells of a round bottom 96 well plate on ice. Pre-immune and immune 
serum samples were diluted 1:50 with washing buffer, mixed with C5065 DFTD tumour cells and incubated 
on ice for 1 h. Cells were washed twice with washing buffer, and incubated with 50 μ l of 10 μ g/ml of a mono-
clonal mouse anti-devil IgG (provided by The Walter and Eliza Hall Institute)8 for 30 min, washed and incu-
bated with 50 μ l of 2 μ g/ml Alexa Fluor 647 conjugated goat anti-mouse IgG antibody (Invitrogen) for 30 min. 
After washing, cells were resuspended in 200 μ l of washing buffer containing 200 ng/ml of the cell viability dye 
4’,6-Diamidino-2-Phenylindole, Dilactate (Sigma-Aldrich). Data acquisition was performed on a BD CANTO II 
flow cytometer (Becton Dickinson). The controls (DFTD cells labelled with the secondary and tertiary antibod-
ies, but no devil serum) did not show background fluorescence. The median fluorescence intensity ratio (MFIR) 
was used to classify the antibody responses. The MFIR is the median fluorescence intensity (MFI) of DFTD cells 
labelled with immune serum divided by the MFI of DFTD cells labelled with pre-immune serum. The responses 
were considered: negative for MFIR < 1.5 times the pre-immune response; low for MFIR of 1.5 to 2 times the 
pre-immune response; medium for MFIR of 2 to 4 times the pre-immune response and strong for MFIR > 4 times 
the pre-immune response.
Histology and immunohistochemistry. Standard haematoxylin and eosin (H&E) and immuno-
histochemical staining were performed on three-micrometre paraffin sections from tumour tissues fixed in 
10% neutral buffered formalin as previously described3. Primary antibodies used for immunohistochemistry 
were as follows: Dako: anti-human CD3 (A0452; 1:300), anti-human HLA-DR - alpha chain (M0746; 1:40); 
Sigma-Aldrich: anti-human periaxin (HPA001868; 1:300). The Walter and Eliza Hall Institute provided the 
anti-devil CD4 (1:50) and anti-devil CD8 (1:100)8. Assessment of the biopsy samples and staining was performed 
by a Pathology Registrar (in human pathology). A light microscope (Olympus-BX50) coupled with a camera 
(Leica-DFC320) was used for visualization and acquisition of the images.
MHC typing. All nine devils and the DFTD tumour cell line used in the study were genotyped at three 
classical MHC-I loci via allele cloning and sequencing. The genotyping protocol described previously4 was 
used with a few modifications. Briefly, genomic DNA was extracted from blood using the QIAamp DNA 
Blood Mini Kit (QIAGEN). MHC peptide-binding domains encoded by exon 2 and 3 of the genes were 
amplified with a pair of multilocus primers (forward: 5′ -GTGTCCCCCCCTCCGTCTCAG-3′ ; reverse: 
5′ -GGGAATAATGGGGCAGGGGAGGT-3′ ) using the Platinum Taq DNA Polymerase High Fidelity Kit 
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(Invitrogen). PCRs were performed on a Bio-Rad MJ Mini Personal Thermal Cycler with the following condi-
tions: 100 °C hot lid; 94 °C initial denaturation for three minutes; 32 cycles of 94 °C denaturation for 30 seconds, 
60 °C annealing for 30 seconds, and 72 °C extension for one minute; and 72 °C final extension for 10 minutes. PCR 
products were purified from agarose gel using QIAquick Gel Extraction Kit (QIAGEN) and cloned in a pGEM T 
Easy Vector (Promega A1360)/JM109 High Efficiency Competent Cells (Promega L1001) cloning system. Sixteen 
to twenty positive clones were picked for each sample and plasmids were extracted using DirectPrep 96 MiniPrep 
Kit (QIAGEN) on a QIAvac Multiwell vacuum manifold (QIAGEN). Purified plasmids were sequenced in both 
directions at the Australian Genome Research Facility. Two independent PCRs were performed for each individ-
ual and sequence variants were considered as real alleles only if they were found in more than one PCR amplifi-
cation. Sequencing results were quality checked in Sequencher 4.1.4 (Gene Codes) and aligned with previously 
reported devil MHC alleles downloaded from GenBank in BioEdit28 and MEGA529.
Production of recombinant devil IFN-γ. A cDNA encoding full length devil IFN-γ (Ensembl reference 
ENSSHAG00000015036) bearing a 5′ Kozak sequence (GAAACC) and a C-terminal fusion to a Gly3His6 tag 
was synthesized by DNA2.0 (California, USA) and subcloned into pFastBac1 as a BamHI-NotI fragment. The 
sequence was confirmed by Sanger sequencing (Micromon, Monash University, VIC) before the construct was 
transformed into DH10MultiBac cells and the bacmid prepared as described previously6,30. Sf21 cells were trans-
fected according to established protocols30, followed by two rounds of viral amplification to generate P3 virus. 
Sf21 cells (0.4 L) were cultured in 2.8 L Fernbach flasks in SF900-II SFM medium (Life Technologies) shaking at 
90 rpm, 27 °C to a density of > 2 × 106 cells/ml before addition of P3 virus and continued incubation for 72 h. The 
volume of P3 virus per 106 cells required for optimal protein yield was determined empirically. Cells were elim-
inated by centrifugation and the supernatant was subjected to tangential flow concentration and three cycles of 
buffer exchange into MT-PBS using a 10 kD molecular weight cut off ultrafilter. The concentrate was subjected to 
Ni2+ chromatography before elution in MT-PBS containing 180 mM NaCl and 250 mM imidazole pH 8, followed 
by concentration by centrifugal ultrafiltration and Superdex-75 gel filtration chromatography with elution in 
MT-PBS. Fractions confirmed to contain devil IFN-γ by SDS-PAGE were pooled, snap frozen in liquid nitrogen 
and stored at − 80 °C until required.
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